Publications and Presentations

Filter By:

ARRY-502

09/21/2010

European Respiratory Society Annual Congress

Safety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies

S. Bell, et al.

Ipatasertib

08/13/2010

Bioorganic & Medicinal Chemistry Letters

Discovery of pyrrolopyrimidine inhibitors of Akt

James F. Blake, et al.

Filanesib

07/01/2010

Molecular Cancer Therapeutics

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

B.J. Tunquist, et al.

Filanesib

06/07/2010

American Society of Clinical Oncology Annual Meeting

A Phase 1 Safety and Pharmacokinetic Study of ARRY-520 in Solid Tumors

P. Goncalves, et al.

Filanesib

06/05/2010

American Society of Clinical Oncology Annual Meeting

Phase 1 Trial of ARRY-520 in Relapsed/Refractory Multiple Myeloma

J.J. Shah, MD, et al.

ARRY-502

05/05/2010

Society for Investigative Dermatology Annual Meeting

A Potent and Selective CRTh2 Antagonist is Efficacious in a Model of Atopic Dermatitis

L. Burgess, et al.

ASLAN001

04/20/2010

American Association for Cancer Research, Chemical and Biological Aspects of Inflammation and Cancer

Pan-ErbB Inhibition by ARRY-334543 is Superior to Selective ErbB Inhibition in a Preclinical Model that Signals Through Multiple ErbB Receptors

R. Blackwell, et al.

GDC-0575

04/20/2010

American Association for Cancer Research Annual Meeting

Single-agent Chk1inhibition is anti-proliferative in leukemia cells in vitro and in vivo

K. D. Davies, et al.

Binimetinib

04/20/2010

American Association for Cancer Research Annual Meeting

Investigation of the growth inhibitory activity of the MEK inhibitor ARRY-438162 in combination with everolimus in a variety of KRas and P13K pathway mutant cancers

B.J. Tunquist, et al.

Binimetinib

04/19/2010

American Association for Cancer Research Annual Meeting

ARRY-162, A Potent and Selective MEK 1 / 2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy

R. Woessner, et al.